Pfizer's attractive dividend yield and low P/E ratio make it appealing. Learn why PFE stock's valuation risks may be higher ...

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have received a consensus rating of “Moderate Buy” from the seventeen ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Alnylam has the FDA approval it sought for Amvuttra in a form of cardiomyopathy associated with rare disease ATTR amyloidosis ...

Ovarian cancer (OC) is the fifth most common cause of cancer-related mortality worldwide and represents the leading cause of death for gynecological malignancies. Nevertheless, over the last years, ...

GERMAN DONER KEBAB boss Simon Wallis is on a mission to transform the food from “something you eat at 2am after 12 pints of ...

Sleep Aids Market Share 2025 Sleep Aids Market is estimated to be valued at USD 83.75 Bn in 2025 and is expected to reach USD 141.77 Bn by ...

Pfizer (NYSE:PFE – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Guggenheim in a research ...

Pfizer Inc. stands out as an undervalued biotech stock with strong dividend potential and ambitious oncology expansion. The company boasts a forward P/E of 8.82, making it significantly cheaper than ...

Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's ...

The Dow Jones Industrial Average lost 0.6% and the S&P 500 shed 1.1% ahead of tonight’s Federal Reserve interest rate ...